Roivant Sciences Ltd.
ROIV
$11.92
$0.110.93%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -72.84% | -16.08% | -42.05% | 22.67% | 78.23% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -72.84% | -16.08% | -42.05% | 22.67% | 78.23% |
| Cost of Revenue | 28.30% | 36.90% | 39.81% | 22.95% | 7.72% |
| Gross Profit | -35.58% | -41.83% | -54.86% | -22.96% | -4.73% |
| SG&A Expenses | 37.88% | 128.37% | 31.07% | 32.29% | 1.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.50% | 81.24% | 35.43% | 27.01% | 5.07% |
| Operating Income | -36.63% | -85.71% | -41.92% | -27.09% | -3.41% |
| Income Before Tax | -1,270.99% | -101.58% | -104.55% | 7.05% | 91.94% |
| Income Tax Expenses | -61.14% | 954.34% | -214.32% | 284.98% | 614.21% |
| Earnings from Continuing Operations | -766.72% | -165.78% | -104.07% | 3.19% | 87.11% |
| Earnings from Discontinued Operations | -- | 100.00% | 658.87% | 50.18% | 207.84% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 33.72% | 46.27% | 118.15% | 85.66% | 4.93% |
| Net Income | -334.38% | -36.63% | -96.68% | 24.36% | 132.66% |
| EBIT | -36.63% | -85.71% | -41.92% | -27.09% | -3.41% |
| EBITDA | -37.47% | -95.25% | -42.81% | -29.73% | -5.49% |
| EPS Basic | -353.51% | -55.10% | -96.32% | 20.78% | 133.70% |
| Normalized Basic EPS | -131.73% | -257.53% | -19.54% | 29.20% | 52.67% |
| EPS Diluted | -354.83% | -56.00% | -96.14% | 20.78% | 133.31% |
| Normalized Diluted EPS | -146.22% | -257.53% | -26.06% | 29.20% | 55.46% |
| Average Basic Shares Outstanding | -7.55% | -11.90% | -9.73% | -4.51% | -3.10% |
| Average Diluted Shares Outstanding | -12.97% | -11.90% | -14.42% | -4.51% | 2.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |